Skip to main content
Clinical Trials/NCT05570019
NCT05570019
Recruiting
N/A

Evaluation of Tissue Perfusion in Patients With Lower Extremity Peripheral Arterial Disease

Medical University Innsbruck1 site in 1 country200 target enrollmentOctober 1, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Peripheral Arterial Disease
Sponsor
Medical University Innsbruck
Enrollment
200
Locations
1
Primary Endpoint
Transcutaneous oxygen pressure
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

In this prospective single-center observational study, arterial perfusion in patients with lower limb peripheral arterial disease will be assessed with standard diagnostic tools (toe pressure, trans-cutaneous oxygen pressure, ankle-brachial index and fluorescence angiography) before and after standard revascularization procedures (open surgery and/or angioplasty).

Detailed Description

Arterial perfusion is an important parameter for the capacity of wound healing in patients with peripheral arterial disease (PAD). Quantifying tissue perfusion in affected patients can help in deciding whether further revascularization is necessary to achieve wound healing and limb salvage. Not only in PAD patients with ulceration, but also in patients with rest pain or life-style limiting claudication, the measurement of arterial perfusion before and after revascularization could influence further treatment regarding surgical/interventional procedures as well as medical treatment. Digital subtraction angiography (DSA) is the gold standard for the evaluation of peripheral arterial outflow and for quality assessment after revascularization. However, angiography only displays the larger arteries and not tissue perfusion itself, which is crucial for wound healing. In this study, the change of tissue perfusion measured with the different standard diagnostic tools (toe pressure, trans-cutaneous oxygen pressure, ankle-brachial index and fluorescence angiography) before and after standard revascularization procedures will be evaluated.

Registry
clinicaltrials.gov
Start Date
October 1, 2022
End Date
December 31, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Medical University Innsbruck
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • patients with symptomatic peripheral arterial disease (Rutherford categories 3-6) requiring revascularization.

Exclusion Criteria

  • patients younger than 18 years
  • patients unable to give consent without legal guardians
  • iodine allergy
  • hyperthyroidism
  • allergy to indocyanine green
  • Glomerular filtration rate \<30ml/min/1.73m2

Outcomes

Primary Outcomes

Transcutaneous oxygen pressure

Time Frame: Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure

Change in transcutaneous oxygen pressure is measured before and after the revascularization procedure.

Secondary Outcomes

  • Secondary patency(Post-procedural (within 5 days) and 3 months after the index procedure)
  • Fluorescence angiography(Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure)
  • Survival(Post-procedural (within 5 days) and 3 months after the index procedure)
  • Primary patency(Post-procedural (within 5 days) and 3 months after the index procedure)
  • Ankle-brachial index (ABI)(Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure)
  • Rutherford category(Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure)
  • Limb salvage(Post-procedural (within 5 days) and 3 months after the index procedure)
  • WIfI stage(Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure)

Study Sites (1)

Loading locations...

Similar Trials